PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.75%
Negative revenue growth while MRVL stands at 4.91%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-8.29%
Negative gross profit growth while MRVL is at 8.94%. Joel Greenblatt would examine cost competitiveness or demand decline.
-0.24%
Negative EBIT growth while MRVL is at 21.01%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
0.24%
Operating income growth under 50% of MRVL's 21.01%. Michael Burry would be concerned about deeper cost or sales issues.
9.66%
Net income growth above 1.5x MRVL's 1.60%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
11.27%
EPS growth above 1.5x MRVL's 3.13%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
8.45%
Diluted EPS growth of 8.45% while MRVL is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
-1.01%
Share reduction while MRVL is at 0.05%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.59%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
8.09%
Dividend growth of 8.09% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-6.68%
Negative OCF growth while MRVL is at 38.12%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
0.76%
FCF growth under 50% of MRVL's 29.18%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
72.41%
10Y revenue/share CAGR under 50% of MRVL's 680.69%. Michael Burry would suspect a lasting competitive disadvantage.
34.31%
5Y revenue/share CAGR under 50% of MRVL's 114.05%. Michael Burry would suspect a significant competitive gap or product weakness.
16.04%
3Y revenue/share CAGR at 50-75% of MRVL's 27.26%. Martin Whitman would question if the firm lags behind competitor innovations.
177.75%
10Y OCF/share CAGR under 50% of MRVL's 5190.81%. Michael Burry would worry about a persistent underperformance in cash creation.
85.39%
Below 50% of MRVL's 258.26%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
1.19%
3Y OCF/share CAGR under 50% of MRVL's 2986.27%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
120.11%
Net income/share CAGR at 75-90% of MRVL's 136.31%. Bill Ackman would press for strategic moves to boost long-term earnings.
96.83%
Below 50% of MRVL's 222.25%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
46.06%
Below 50% of MRVL's 236.87%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
22.64%
Positive growth while MRVL is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
19.66%
Below 50% of MRVL's 52.93%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
22.49%
3Y equity/share CAGR at 75-90% of MRVL's 28.61%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
511.63%
Dividend/share CAGR of 511.63% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
336.24%
Dividend/share CAGR of 336.24% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
29.79%
3Y dividend/share CAGR of 29.79% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-13.45%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
6.74%
Inventory growth well above MRVL's 0.97%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
5.95%
Similar asset growth to MRVL's 5.79%. Walter Schloss finds parallel expansions or investment rates.
5.84%
75-90% of MRVL's 7.53%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
No Data
No Data available this quarter, please select a different quarter.
-6.00%
Our R&D shrinks while MRVL invests at 0.07%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-0.26%
We cut SG&A while MRVL invests at 14.49%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.